Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seeing Machines forms eye disease master pact with Australian National University:

This article was originally published in Clinica

Executive Summary

Canberra, Australia-based Seeing Machines has signed a master development and commercialisation deal with the Australian National University (ANU) to develop diagnostics for eye diseases, such as glaucoma. Under the agreement, computer vision systems maker Seeing Machines will provide the university, also based in Canberra, with equipment, software and know-how, including non-commercialised proprietary technologies. In return, the company has first rights to exclusively commercialise any new IP developed under the pact. The company and the ANU have already teamed up on the development of the company's TrueField Analyzer, for helping doctors diagnose and manage a range of eye diseases, including glaucoma, age-related macular degeneration (AMD) and diabetic retinopathy. The device has yet to reach the market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel